Brexogen
- Biotech or pharma, therapeutic R&D
Brexogen is a clinical-stage biotech company developing therapeutic exosomes as a cell-free regenerative medicine.
Our core technology, the BG-platform, is designed to generate therapeutic exosomes that target autoimmune diseases and metabolic diseases requiring regenerative treatment. The BG-platform consists primarily of iMSCs, referred to as BxC, which produce exosomes with high purity and homogeneity. In combination with a proprietary priming process, BxC cells are stimulated to secrete exosomes with enhanced therapeutic properties.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}